<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695237</url>
  </required_header>
  <id_info>
    <org_study_id>M16-904</org_study_id>
    <nct_id>NCT03695237</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and efficacy of a leuprolide
      acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are
      either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have
      been previously treated with a GnRHa.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">February 25, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with suppression of GnRHa-stimulated luteinizing hormone (LH)(&lt;4 milli-international units per milliliter (mlU/mL))</measure>
    <time_frame>At Week 24</time_frame>
    <description>It is measured by peak LH stimulation test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of female participants with suppression of basal estradiol to &lt;20 pg/mL</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Female participants with suppression of basal estradiol to &lt; 20 pg/mL are assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of male participants with suppression of testosterone to &lt;30 ng/dL</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Male participants with suppression of testosterone to &lt; 30 ng/dL are assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with maintenance of suppression of GnRHa-stimulated LH (&lt;4 mlU/mL)</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Participants with maintenance of suppression of GnRHa-stimulated LH (&lt;4 mlU/mL) are assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of female participants with maintenance of suppression of basal estradiol to &lt;20 pg/mL</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Female participants with maintenance of suppression of basal estradiol to &lt; 20 pg/mL are assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of male participants with maintenance of suppression of testosterone to &lt;30 ng/dL</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Male participants with maintenance of suppression of testosterone to &lt; 30 ng/dL are assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with suppression of the physical signs of puberty</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Breast development in females, testicular volume or genital development in males will be assessed using modified Tanner staging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental growth rate</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Incremental growth rate (cm/year) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of change from baseline in bone age vs chronological age</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Ratio of change from baseline in bone age vs chronological age is assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with suppression of GnRHa-stimulated luteinizing hormone (LH)(&lt;4 mlU/mL)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>It is measured by peak LH stimulation test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Central Precocious Puberty (CPP)</condition>
  <arm_group>
    <arm_group_label>Participants receiving Leuprolide Acetate (LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Central Precocious Puberty receiving LA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate (LA)</intervention_name>
    <description>It is administered intramuscularly as an injection</description>
    <arm_group_label>Participants receiving Leuprolide Acetate (LA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with CPP who are naïve to treatment with a gonadotropin-releasing hormone
             agonist (GnRHa) (females 2 - 8 years of age, or males 2 - 9 years of age) or who have
             been on standard GnRHa therapy for at least 6 months (females 2 - 10 years of age, or
             males 2 - 11 years of age).

          -  No history of clinically significant medical conditions or any other reason that the
             investigator determines would make the participant an unsuitable candidate to receive
             study drug.

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Endocrinology Associates /ID# 200629</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806-1651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hosp San Diego /ID# 202491</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Children's Hospital /ID# 201645</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Endocrine Associates /ID# 201089</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemour Child Clin FL, US /ID# 201331</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hosp Children /ID# 201624</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Van Meter Pediatric Endocrinology /ID# 201688</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318-2538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University /ID# 200526</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital /ID# 202396</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-4724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center /ID# 203327</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota /ID# 200508</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens Mercy Hosp and Clin /ID# 200221</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UBMD - Pediatrics /ID# 201978</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Med Mt. Sinai /ID# 200675</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma /ID# 200659</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135-2527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Ctr /ID# 200287</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hosp of PA (CHOP) /ID# 203846</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cook Children's Med. Center /ID# 212937</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute Health Sys /ID# 202188</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Endocrine Research Associates /ID# 200131</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Precocious Puberty (CPP)</keyword>
  <keyword>Leuprolide Acetate (LA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

